证券代码：301075 证券简称：多瑞医药 公告编号：2025-098 西藏多瑞医药股份有限公司 关于向控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召开第二届董事会第二十三次会议、于 2025 年 10 月 30 日召开 2025 年第一次临时股东会，审议通过了《关于向控股子公司增加担 保额度的议案》，同意公司为控股子公司湖北鑫承达化工有限公司（以 下简称"鑫承达"）、四川多瑞药业有限公司（以下简称"四川多瑞"） 合计增加不超过 13,000 万元人民币的连带责任保证担保额度。鑫承 达少数股东按出资比例提供同等担保或者反担保；四川多瑞为公司控 股子公司，公司能够控制其经营及管理，有效地监督和管控为其提供 的担保，担保风险可控，不会损害上市公司利益，因此其少数股东不 提供同等担保或者反担保。具体内容详见公司于 2025 年 10 月 14 日 在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 二、担保进展情况 近日 ...

Core Viewpoint - Duori Pharmaceutical, established in December 2016 and listed on the Shenzhen Stock Exchange in September 2021, focuses on the research and development of chemical drug formulations and has several core technologies in this field [1] Business Performance - For Q3 2025, Duori Pharmaceutical reported revenue of 137 million, ranking 103rd among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which had revenue of 32.664 billion, and the industry average of 2.8 billion [2] - The net profit for the same period was -113 million, placing the company 96th in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion, with the industry average at 299 million [2] Financial Ratios - As of Q3 2025, Duori Pharmaceutical's debt-to-asset ratio was 55.73%, an increase from 28.40% in the previous year and above the industry average of 35.26%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 4.63%, a significant drop from 40.75% in the previous year and below the industry average of 57.17%, reflecting weak profitability [3] Executive Compensation - The chairman and general manager, Deng Yong, received a salary of 609,000 in 2024, a decrease of 31,200 from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.60% to 6,361, while the average number of circulating A-shares held per account increased by 19.90% to 12,600 [5]

北京中伦（武汉）律师事务所 关于西藏多瑞医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 北京中伦（武汉）律师事务所接受西藏多瑞医药股份有限公司（以下简称"公 司"）的委托，指派本所律师出席了公司 2025 年第一次临时股东大会（以下简 称"本次股东大会"），并依法进行现场见证。现根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则》（以下简称 "《网络投票实施细则》"）等法律法规和规范性文件以及《西藏多瑞医药股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，就公司本次股东大 会的有关事宜出具法律意见书。 本所律师对公司本次股东大会的召集、召开程序的合法性、本次股东大会召 集人资格的合法有效性、出席本次会议人员资格的合法有效性及会议表决程序、 表决结果的合法有效性，发表法律意见。 二〇二五年十月 北京中伦（武汉）律师事务所关于 西藏多瑞医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：西藏多瑞医药股份有限公司 本所律师依据对法律意见书出具日以前已经发生或存在的事 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-097 西藏多瑞医药股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有出现否决议案的情形； 2.本次股东会没有涉及变更前次股东会决议的情形。 一、会议召开和出席情况 西藏多瑞医药股份有限公司（以下简称"公司"或"多瑞医药"） 2025年第一次临时股东会通知于2025年10月14日以公告形式发出， 具体内容详见当日公司于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的公告。 （一）会议召开情况 1、会议召开时间： （1）现场会议时间：2025 年 10 月 30 日（星期四）14:30 （2）网络投票时间：2025 年 10 月 30 日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 10 月 30 日 09:15-09:25，09:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网系统（http://wltp.c ...

Core Viewpoint - The company, Duorui Pharmaceutical, emphasizes its commitment to establishing a robust corporate governance structure and enhancing communication with investors, particularly small and medium shareholders [1] Group 1: Corporate Governance - The company will adhere to the requirements of the Company Law, the Code of Corporate Governance for Listed Companies, and other relevant laws and regulations to establish a governance structure composed of the shareholders' meeting, board of directors, and management [1] - There will be efforts to further improve related systems to ensure effective governance [1] Group 2: Investor Communication - The company plans to strengthen communication with investors through various channels, actively engaging with shareholders, especially small and medium shareholders, to gather their opinions and demands [1] - The company commits to timely responses to concerns raised by small and medium shareholders [1] Group 3: Information Disclosure - The company aims to continuously enhance the quality of information disclosure, ensuring that it is truthful, accurate, complete, timely, and fair [1]

Core Viewpoint - Duori Pharmaceutical announced on October 24 that the share transfer requires approval from the company's shareholders meeting and compliance confirmation from the Shenzhen Stock Exchange, highlighting the need for adherence to legal procedures and information disclosure obligations to protect the interests of the company and minority investors [1] Summary by Relevant Sections - **Share Transfer Process** - The share transfer is subject to approval from the shareholders meeting and may require additional regulatory approvals [1] - **Compliance and Legal Obligations** - The company emphasizes the importance of following relevant laws and regulations in the process, ensuring that all legal procedures are strictly adhered to [1] - **Investor Communication** - Duori Pharmaceutical will keep investors informed of any developments through official announcements, reinforcing its commitment to transparency [1]

Core Viewpoint - The company emphasizes the importance of market value management and plans to enhance information disclosure, optimize market value management mechanisms, and improve communication with investors to convey the company's value effectively [1] Group 1 - The company is committed to improving its market value management efforts [1] - The company will continue to enhance the quality of information disclosure [1] - The company aims to optimize its market value management mechanisms [1] Group 2 - The company intends to improve the quality of communication and interaction with investors [1] - The company will ensure timely communication of its value to the capital market [1]

Core Viewpoint - The company, Tibet Duori Pharmaceutical Co., Ltd., has approved a cash management plan to utilize idle self-owned funds of up to 150 million yuan to enhance fund efficiency and achieve asset preservation and appreciation [1][2]. Investment Plan Details - The cash management plan is designed with the principles of prioritizing safety, matching liquidity, and supplementing returns, with a maximum investment amount of 150 million yuan and a strict investment period not exceeding 12 months [2]. - The funds will be invested in low-risk products issued by banks or other financial institutions, explicitly excluding stocks, derivatives, and unsecured bonds [3]. Funding Source and Decision Mechanism - The cash management funds will solely come from the company's idle self-owned funds, without involving raised or borrowed funds. The board has authorized management to make investment decisions within the set limits, with the finance department responsible for specific operations [4]. Risk Control and Supervision Mechanism - A multi-layered risk prevention system has been established, including a product selection mechanism that limits investments to low-risk products from state-owned banks or mainstream financial institutions, a dynamic monitoring mechanism for real-time tracking of product value changes, and an internal supervision mechanism for regular checks by independent directors and the supervisory board [5]. Impact on Company Operations - The cash management plan will not affect the company's main business operations, as it is implemented while ensuring the funding needs for daily production and project construction. The scientific allocation of idle funds is expected to enhance fund yield and further increase company profits, creating more value for shareholders [6]. Validity of the Resolution - The resolution is valid for 12 months from the date of board approval, with specific investment products to be selected based on market conditions [7].

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and an increase in net losses for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 137 million yuan, representing a year-on-year decrease of 43.07% [1] - The net loss attributable to shareholders of the listed company was 79.7277 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 84.9485 million yuan [1] - The basic loss per share was 1.0064 yuan [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and an increase in net losses for the third quarter of the year [1] Financial Performance - The company recorded a revenue of 137 million yuan for the first three quarters, representing a year-on-year decrease of 43.07% [1] - The net loss for the period amounted to 79.72 million yuan, with a non-recurring net loss of 84.95 million yuan [1] - Basic earnings per share were reported at -1.0064 yuan [1]